Randomised Phase II Study Evaluating Trifluridine/tipiracil (FTD/TPI) Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients with HER2-negative Locally Advanced, Recurrent or Metastatic Gastric, Oesophageal or Junctional Adenocarcinoma (aga/geja) (PRODIGE 73-LOGICAN)
ANNALS OF ONCOLOGY(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined